Parathyroid hormone assay standardization in CKD-MBD: resolving heterogeneity for precision medicine

Area of Science:

• Endocrinology
• Nephrology
• Biochemistry

Background:

• Parathyroid hormone (PTH) is critical for calcium and bone metabolism.
• Accurate PTH measurement is essential for diagnosing endocrine and bone diseases, particularly chronic kidney disease-mineral and bone disorder (CKD-MBD).
• Current immunoassays face challenges due to PTH's molecular heterogeneity.

Purpose of the Study:

• To review the limitations of current PTH measurement methods.
• To highlight standardization challenges in PTH testing.
• To discuss emerging strategies, including mass spectrometry, for reliable PTH measurement in CKD management.

Main Methods:

• Review of existing literature on PTH measurement technologies.
• Analysis of technological limitations of immunoassays.
• Evaluation of mass spectrometry advancements for PTH quantification.

Main Results:

• Immunoassays struggle with PTH's molecular heterogeneity, impacting diagnostic accuracy.
• Mass spectrometry (MS) offers structural specificity and improved sensitivity for intact 1-84 PTH.
• MS can identify clinically relevant PTH fragments, aiding in CKD-MBD assessment.

Conclusions:

• Technological limitations and standardization issues hinder reliable PTH testing.
• Mass spectrometry represents a promising advancement for accurate PTH measurement.
• Improved PTH testing strategies are crucial for effective CKD-MBD management.